CD8A and neoplasm: The reason for the continuation of the Phase III trial (NCT04203485) may be because proper reduction of angiogenesis can improve PD-1/PD-L1 blocking through decreasing tumor-associated macrophage recruitment, boosting CD8+ T cell infiltration, and alleviating hypoxia.